"Encouraged by the success of checkpoint inhibitors in fighting some cancers, many companies are developing antibodies that block the LAG-3-MHC-II interaction, including Tesaro(TSR033), Novartis (LAG525), Bristol-Myers Squibb (relatlimab) and F-star (FS118). The safety and efficacy of these candidate immunotherapies are being evaluated in trials for several advanced cancers."
Soooo....could someone with a better understanding of the science than I, please explain if our little Efti has been on the right track?
Thanks in advance.
IMM Price at posting:
3.1¢ Sentiment: Buy Disclosure: Held
